|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:dextroamphetamine
amphetamine
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06BA02
|
|
gptkbp:brand
|
mixed amphetamine salts
|
|
gptkbp:contraindication
|
gptkb:cardiovascular_disease
glaucoma
hyperthyroidism
history of drug abuse
|
|
gptkbp:discoveredBy
|
1996
|
|
gptkbp:drugClass
|
amphetamine
stimulant
|
|
gptkbp:eliminationHalfLife
|
9-14 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:extended-release_capsule_(Adderall_XR)
immediate-release tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Adderall
|
|
gptkbp:interactsWith
|
gptkb:proton_pump_inhibitors
gptkb:monoamine_oxidase_inhibitors
antihypertensives
antidepressants
antacids
other stimulants
|
|
gptkbp:legalStatus
|
prescription only
Schedule II controlled substance (US)
|
|
gptkbp:manufacturer
|
gptkb:Shire
gptkb:Teva_Pharmaceuticals
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
gptkb:depression
confusion
death
fatigue
tremor
muscle pain
aggression
coma
panic
restlessness
hallucinations
weakness
rapid breathing
dark colored urine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
abuse
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
anxiety
loss of appetite
increased heart rate
insomnia
dry mouth
|
|
gptkbp:soldIn
|
gptkb:European_Union
gptkb:Japan
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:Annie_Edison
|
|
gptkbp:bfsLayer
|
5
|